BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ambrosini V, Kunikowska J, Baudin E, Bodei L, Bouvier C, Capdevila J, Cremonesi M, de Herder WW, Dromain C, Falconi M, Fani M, Fanti S, Hicks RJ, Kabasakal L, Kaltsas G, Lewington V, Minozzi S, Cinquini M, Öberg K, Oyen WJG, O'Toole D, Pavel M, Ruszniewski P, Scarpa A, Strosberg J, Sundin A, Taïeb D, Virgolini I, Wild D, Herrmann K, Yao J. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer 2021;146:56-73. [PMID: 33588146 DOI: 10.1016/j.ejca.2021.01.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Fani M, Mansi R, Nicolas GP, Wild D. Radiolabeled Somatostatin Analogs-A Continuously Evolving Class of Radiopharmaceuticals. Cancers (Basel) 2022;14:1172. [PMID: 35267479 DOI: 10.3390/cancers14051172] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Wang K, Tepper JE. Radiation therapy-associated toxicity: Etiology, management, and prevention. CA Cancer J Clin 2021. [PMID: 34255347 DOI: 10.3322/caac.21689] [Reference Citation Analysis]
3 Imperiale A, Meuter L, Pacak K, Taïeb D. Variants and Pitfalls of PET/CT in Neuroendocrine Tumors. Semin Nucl Med 2021;51:519-28. [PMID: 33838874 DOI: 10.1053/j.semnuclmed.2021.03.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
4 Refardt J, Hofland J, Wild D, Christ E. Molecular Imaging of Neuroendocrine Neoplasms. J Clin Endocrinol Metab 2022;107:e2662-70. [PMID: 35380158 DOI: 10.1210/clinem/dgac207] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Christ E, Wild D, Refardt J. Molecular Imaging in neuroendocrine neoplasias Review in Quarterly Medical Review. La Presse Médicale 2022. [DOI: 10.1016/j.lpm.2022.104115] [Reference Citation Analysis]
6 Lee ONY, Tan KV, Tripathi V, Yuan H, Chan WW, Chiu KWH. The Role of 68Ga-DOTA-SSA PET/CT in the Management and Prediction of Peptide Receptor Radionuclide Therapy Response for Patients With Neuroendocrine Tumors: A Systematic Review and Meta-analysis. Clin Nucl Med 2022. [PMID: 35485851 DOI: 10.1097/RLU.0000000000004235] [Reference Citation Analysis]
7 Kunikowska J, Ambrosini V, Herrmann K. EANM Focus 3: The International Conference on Molecular Imaging and Theranostics in Neuroendocrine Tumours-the consensus in a nutshell. Eur J Nucl Med Mol Imaging 2021;48:1276-7. [PMID: 33624150 DOI: 10.1007/s00259-021-05262-x] [Reference Citation Analysis]
8 Ambrosini V, Zanoni L, Filice A, Lamberti G, Argalia G, Fortunati E, Campana D, Versari A, Fanti S. Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors. Cancers (Basel) 2022;14:1055. [PMID: 35205805 DOI: 10.3390/cancers14041055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Muñoz de Nova JL, Hernando J, Sampedro Núñez M, Vázquez Benítez GT, Triviño Ibáñez EM, del Olmo García MI, Barriuso J, Capdevila J, Martín-Pérez E. Management of incidentally discovered appendiceal neuroendocrine tumors after an appendicectomy. World J Gastroenterol 2022; 28(13): 1304-1314 [DOI: 10.3748/wjg.v28.i13.1304] [Reference Citation Analysis]
10 Chiodini I, Gennari L. Grand Challenge in Adrenal Endocrinology: Is the Legacy of the Past a Challenge for the Future of Precision Medicine? Front Endocrinol (Lausanne) 2021;12:747006. [PMID: 34539585 DOI: 10.3389/fendo.2021.747006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Zhang H, Koumna S, Pouliot F, Beauregard JM, Kolinsky M. PSMA Theranostics: Current Landscape and Future Outlook. Cancers (Basel) 2021;13:4023. [PMID: 34439177 DOI: 10.3390/cancers13164023] [Reference Citation Analysis]
12 Rizzo A, Annunziata S, Salvatori M. Side effects of theragnostic agents currently employed in clinical practice. Q J Nucl Med Mol Imaging 2021;65:315-26. [PMID: 34881848 DOI: 10.23736/S1824-4785.21.03411-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Spada F, Rossi RE, Kara E, Laffi A, Massironi S, Rubino M, Grimaldi F, Bhoori S, Fazio N. Carcinoid Syndrome and Hyperinsulinemic Hypoglycemia Associated with Neuroendocrine Neoplasms: A Critical Review on Clinical and Pharmacological Management. Pharmaceuticals (Basel) 2021;14:539. [PMID: 34199977 DOI: 10.3390/ph14060539] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Merola E, Michielan A, Rozzanigo U, Erini M, Sferrazza S, Marcucci S, Sartori C, Trentin C, de Pretis G, Chierichetti F. Therapeutic strategies for gastroenteropancreatic neuroendocrine neoplasms: State-of-the-art and future perspectives. World J Gastrointest Surg 2022; 14(2): 78-106 [DOI: 10.4240/wjgs.v14.i2.78] [Reference Citation Analysis]
15 Konukiewitz B, Jesinghaus M, Kasajima A, Klöppel G. Neuroendocrine neoplasms of the pancreas: diagnosis and pitfalls. Virchows Arch 2021. [PMID: 34647171 DOI: 10.1007/s00428-021-03211-5] [Reference Citation Analysis]
16 Jin Y, Liu B, Younis MH, Huang G, Liu J, Cai W, Wei W. Next-Generation Molecular Imaging of Thyroid Cancer. Cancers (Basel) 2021;13:3188. [PMID: 34202358 DOI: 10.3390/cancers13133188] [Reference Citation Analysis]
17 Galgano SJ, Iravani A, Bodei L, El-haddad G, Hofman MS, Kong G. Imaging of Neuroendocrine Neoplasms: Monitoring Treatment Response— AJR Expert Panel Narrative Review. American Journal of Roentgenology. [DOI: 10.2214/ajr.21.27159] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
18 Rufini V, Lorusso M, Inzani F, Pasciuto T, Triumbari EKA, Grillo LR, Locco F, Margaritora S, Pescarmona E, Rindi G. Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study. Eur J Nucl Med Mol Imaging 2022. [PMID: 35674739 DOI: 10.1007/s00259-022-05848-z] [Reference Citation Analysis]
19 Ciobanu OA, Martin S, Fica S. Perspectives on the diagnostic, predictive and prognostic markers of neuroendocrine neoplasms (Review). Exp Ther Med 2021;22:1479. [PMID: 34765020 DOI: 10.3892/etm.2021.10914] [Reference Citation Analysis]
20 Hope TA, Pavel M, Bergsland EK. Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time? J Clin Oncol 2022;:JCO2200176. [PMID: 35649195 DOI: 10.1200/JCO.22.00176] [Reference Citation Analysis]
21 Theiler D, Cattaneo M, Dierickx LO, Igaz P, Grozinsky-Glasberg S, Bournaud C, O'Dorisio T, O'Dorisio MS, Wild D, Christ E, Nicolas GP. Safety and Efficacy of Peptide-Receptor Radionuclide Therapy in Elderly Neuroendocrine Tumor Patients. Cancers (Basel) 2021;13:6290. [PMID: 34944910 DOI: 10.3390/cancers13246290] [Reference Citation Analysis]
22 O'neill E, Cornelissen B. Know thy tumour: Biomarkers to improve treatment of molecular radionuclide therapy. Nuclear Medicine and Biology 2022. [DOI: 10.1016/j.nucmedbio.2022.02.004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Hosono M, Takenaka M, Monzen H, Tamura M, Kudo M, Nishimura Y. Cumulative radiation doses from recurrent PET/CT examinations. Br J Radiol 2021;:20210388. [PMID: 34111964 DOI: 10.1259/bjr.20210388] [Reference Citation Analysis]
24 Tong D, Zhang Y, Jiang J, Bi G. Identification of a VHL gene mutation in atypical Von Hippel-Lindau syndrome: genotype-phenotype correlation and gene therapy perspective. Cancer Cell Int 2021;21:685. [PMID: 34923986 DOI: 10.1186/s12935-021-02386-w] [Reference Citation Analysis]
25 Manneh Kopp R, Espinosa-Olarte P, Alonso-Gordoa T. Diagnosis in Neuroendocrine Neoplasms: From Molecular Biology to Molecular Imaging. Cancers (Basel) 2022;14:2514. [PMID: 35626118 DOI: 10.3390/cancers14102514] [Reference Citation Analysis]
26 Staanum PF, Frellsen AF, Olesen ML, Iversen P, Arveschoug AK. Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates. EJNMMI Phys 2021;8:78. [PMID: 34773508 DOI: 10.1186/s40658-021-00422-2] [Reference Citation Analysis]
27 Ahmadi Bidakhvidi N, Goffin K, Dekervel J, Baete K, Nackaerts K, Clement P, Van Cutsem E, Verslype C, Deroose CM. Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies. Cancers (Basel) 2021;14:129. [PMID: 35008293 DOI: 10.3390/cancers14010129] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Treglia G, Sadeghi R, Giovinazzo F, Galiandro F, Annunziata S, Muoio B, Kroiss AS. PET with Different Radiopharmaceuticals in Neuroendocrine Neoplasms: An Umbrella Review of Published Meta-Analyses. Cancers (Basel) 2021;13:5172. [PMID: 34680321 DOI: 10.3390/cancers13205172] [Reference Citation Analysis]
29 Krokhmal AA, Kwatra N, Drubach L, Weldon CB, Janeway KA, DuBois SG, Kamihara J, Voss SD. 68 Ga-DOTATATE PET and functional imaging in pediatric pheochromocytoma and paraganglioma. Pediatr Blood Cancer 2022;69:e29740. [PMID: 35484995 DOI: 10.1002/pbc.29740] [Reference Citation Analysis]